Predictors of virologic failure in hiv/aids patients treated with highly active antiretroviral therapy in brasília, Brazil during 2002-2008

Drug Target Insights

Volumn 2011, Issue 5, 2011, Pages 33-41

  Bello, Edson José Monteiro ^a   Correia, Amabel Fernandes ^b   Marins, José Ricardo Pio ^a   Merchan Hamann, Edgar ^c   Kanzaki, Luis Isamu Barros ^d  

^a Public Health Laboratory   (Brazil)

^b Health Sciences Nucleus of Parasitology   (Brazil)

^c Faculty of health Sciences   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Antiretroviral therapy; Brasilia; Epidemiology; Tuberculosis coinfection

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; CELL DENSITY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT ASSESSMENT; PREDICTION; RISK FACTOR; TUBERCULOSIS; VIRUS LOAD;

EID: 83755188164     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S7527     Document Type: Article

References (26)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. Jun 15, 1997;126(12):946-54.
2. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F. Misclassi-fcation of frst-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. Aug 1, 2009;49(3):454-62.
3. Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodefciency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol. Jul 2008;46(7):2206-11.
4. Pinganaud C, Goujard C. Management of antiretroviral treatment in HIV-infected patients exhibiting virologic failure. Presse Med. Jun 22, 2002;31(22):1034-40.
5. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis. Feb 1, 2007;44(3):453-5.
6. + T-lymphocyte measures in the treatment of individuals infected with human immunodefciency virus type 1. A review for clinical practitioners. Arch Intern Med. Jul 25, 1994;154(14):1561-73.
7. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. Apr 2003;8(2):127-36.
8. + T cells and viral load of children with AIDS: a population-based study. AIDS Res Hum Retroviruses. Sep 2004;20(9):927-31.
9. Battegay M, Fehr J, Fluckiger U, Elzi L. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother. Jul 2008; 62(1):41-4.
10. Melchior R, Nemes MI, Alencar TM, Buchalla CM. Challenges of treatment adherence by people living with HIV/AIDS in Brazil. Rev Saude Publica. Dec 2007;41 Suppl 2: 87-93.
11. CDC revises HIV classifcation system, AIDS defnition. W V Med J. Feb 1993;89(2):74.
12. Brazil MoH, Secretariat of Health Surveillance, National STD and AIDS. Recommendations for antiretroviral therapy in adults and adolescents infected with HIV. 2008. Available: http://bvsms.saude.gov.br/bvs/ publicacoes/recomendacao_terapia.pdf access: 28/05/2011.
13. Brazil MoHSSoH, National STD AIDS. Quick Reference for the ARV Drug Dispensing SICLOM. 2007. Available: http://siclom.aids.gov.br access: 28.05.2011.
14. Brazil NPfPaCoVH. National Program for Prevention and Control of Viral Hepatitis. 2005. National Program for Prevention and Control of Viral Hepatitis http://bvsms.saude.gov.br/bvs/politicas/hepatites_aconselhamento.pdf access: 28.05.2011.
15. Brazil MoH, Department of health Policy, Department of Primary Care. Technical Manual for the Control of Tuberculosis. 2002. Available to: http:// bvsms.saude.gov.br/bvs/publicacoes/guia_controle_tuberculose.pdf access: 28.05.2011.
16. Faucher JF, Challier B, Chirouze C, Drobacheff C, Fischer P, Lang JM. Predictive factors of virological response to primary antiretroviral treatment. Presse Med. Mar 13, 2004;33(5):310-5.
17. Johnson K, Way A. Risk factors for HIV infection in a national adult population: evidence from the 2003 Kenya Demographic and Health Survey. J Acquir Immune Defc Syndr. Aug 15, 2006;42(5):627-36.
18. Cole SR, Hernan MA, Anastos K, Jamieson BD, Robins JM. Determining the effect of highly active antiretroviral therapy on changes in human immu-nodefciency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol. Jul 15, 2007;166(2):219-27.
19. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. Nov 28, 2001;286(20):2560-7.
20. Asjo B, Langeland N. Drug resistance in HIV infection. Tidsskr Nor Laegeforen. Nov 20, 2008;128(22):2593-6.
21. Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defc Syndr. Dec 1, 2001;28(4):313-9.
22. Piliero PJ. Early factors in successful anti-HIV treatment. J Int Assoc Physicians AIDS Care (Chic Ill). Jan-Mar 2003;2(1):10-20.
23. Moreno Cuerda VJ, Rubio Garcia R, Morales Conejo M. New therapeutic options in protracted HIV-infected patients with virological failure. Med Clin (Barc). Jan 26, 2008;130(2):66-70.
24. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M. Determinants of virological failure after successful viral load suppression in frst-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7): 927-36.
25. Bekker LG, Orrell C, Reader L, Matoti K, Cohen K, Martell R. Antiret-roviral therapy in a community clinic-early lessons from a pilot project. S Afr Med J. Jun 2003;93(6):458-62.
26. von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodefciency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis. Aug 2011;15(8):1087-92.